Liu Yang, Guohong Liu, Yirong Li, 等. The emergence of tumor-infiltrating lymphocytes in nasopharyngeal carcinoma: Predictive value and immunotherapy implications[J]. Genes & Diseases, 2022,9(5).
Liu Yang, Guohong Liu, Yirong Li, et al. The emergence of tumor-infiltrating lymphocytes in nasopharyngeal carcinoma: Predictive value and immunotherapy implications[J]. Genes & Diseases, 2022,9(5).
Liu Yang, Guohong Liu, Yirong Li, 等. The emergence of tumor-infiltrating lymphocytes in nasopharyngeal carcinoma: Predictive value and immunotherapy implications[J]. Genes & Diseases, 2022,9(5). DOI: 10.1016/j.gendis.2021.07.002.
Liu Yang, Guohong Liu, Yirong Li, et al. The emergence of tumor-infiltrating lymphocytes in nasopharyngeal carcinoma: Predictive value and immunotherapy implications[J]. Genes & Diseases, 2022,9(5). DOI: 10.1016/j.gendis.2021.07.002.
The emergence of tumor-infiltrating lymphocytes in nasopharyngeal carcinoma: Predictive value and immunotherapy implications
摘要
Abstract
The clinical study of nasopharyngeal carcinoma (NPC) often reveals a large number of lymphocytes infiltrating the primary tumor site. As an important part of the tumor microenvironment
tumor-infiltrating lymphocytes (TILs) do not exist alone but as a complex multicellular population with high heterogeneity. TILs play an extremely significant role in the occurrence
development
invasion and metastasis of NPC. The latest research shows that they participate in tumorigenesis and treatment
and the composition
quantity
functional status and distribution of TILs subsets have good predictive value for the prognosis of NPC patients. TILs are an independent prognostic factor for TNM stage and significantly correlated with better prognosis. Additionally
adoptive immunotherapy using anti-tumor TILs has achieved good results in a variety of solid tumors including NPC. This review evaluates recent clinical and preclinical studies of NPC
summarizes the role of TILs in promoting and inhibiting tumor growth
evaluates the predictive value of TILs
and explores the potential benefits of TILs-based immunotherapy in the treatment of NPC.